



# ***A systems chemical biology approach to infer and design metabolic networks***

**Jean-Loup Faulon,  
Evry University, UniverSud Paris  
Epigenomics Program, Genopole®, CNRS  
523 Terrasses de l'Agora  
91034 ÉVRY cedex  
jean-loup.faulon@epigenomique.genopole.fr  
<http://jfaulon.wikispaces.com>**




# *Inference and design of chemicals and biological sequences and networks*


## • Structure Inference



## • Property & activity prediction



## • Design



# Prediction and inference using residue and atom neighborhood

## Residue neighborhood (strings, k-mers)

...EKKAI**P**QEKK...

Leslie  
*et al.*  
PSB  
2002


k=1 (h=0)    **P**  
k=3 (h=1)    **IPQ**  
k=5 (h=2)    **AIPQE**

### Protein string spectrum

$k=3 \sigma(\text{EKKAI**P**QEKK}) =$   
EKK KKA KAI AIP IPQ PQE QEK  
**( 2 1 1 1 1 1 1 )**

Sequence assembly  
Function prediction

## Atom neighborhood (atom signature)



h=0    **C**  
h=1    **C(C    =C    O)**  
h=2    **C(C(=C) =C(C) O(H))**  
h=3    **C(C(=C(**C**))=C(C(=**C**))O(H))**

Faulon *et al.* J.  
Chem. Info. 1994

canonization:  
Faulon *et al.* J.  
Chem. Info. 2004

### Molecular signature

$h=1 \sigma(\text{Tyrosine}) =$   
C (C =C O) C (C =C) C (C C =C) O (C H) C (C H H)  
**( 1 4 1 1 1 )**

Structure elucidation  
Property prediction

**QSAR & kernel methods to detect homology and similarity**

# Chemical structure-activity relationships: examples with atom neighborhood

- Atom neighborhood/signature  
(1994)

- Tripos' Hologram HQSAR  
(1996)

- Filimonov & Poroikov multilevel  
atom-neighborhood PASS  
descriptors (2001)

- Solov'ev, Varnek , & Wipff,  
sequences & augmented atoms  
(2001)

- Glen & Bender atom environment  
(2003)

HIV-1 Protease Inhibitors IC <sub>50</sub> , 130 compounds in training set								
Height	0	1	2	3	4	5	6	7
q <sup>2</sup> (MLR)	0.75	0.80	0.77	0.81	0.77	0.69	0.65	0.66
Log P, 1,000 compounds in training set								
q <sup>2</sup> (MLR)	0.61	0.83	0.78	0.58	0.31	0.23	0.16	0.11
Glass Transition T <sub>g</sub> 262 polymers in training set								
q <sup>2</sup> (MLR)	0.65	0.78	0.75	0.81	0.65	0.60	0.44	0.32
q <sup>2</sup> (Linear SVR)	0.64	0.80	0.81	0.81	0.73	0.22	0.29	0

Faulon et al. JMGM 2002, JCICS 2003-a&b, JCAMD 2005, Ind. Eng. Chem. Res 2005, JCIM 2006, JMGM 2009

# *Strings spectra are prevalent in many computational biology applications*

## *Protein structure prediction*

- SCOP family prediction *Leslie et al., PSB2002.*
- Beta sheet ordering: *Brown, Martin, Strauss, Faulon, J. Mol. Model., 2006*

## *Protein functional annotation*

- Subcellular localization prediction: *Hua & Sun, Bioinformatics 2001*
- TIGR Protein function prediction: *Martin, Brown, Faulon, Genome-To-Life review 2005*
- Catalytic activity prediction (EC number second level): *Kunik et al. CSB2005*
- Enzyme (EC) number prediction: *Faulon et al. Bioinformatics 2008*
- Phosphorylation site prediction, *Gray et al. Annals Operation Research 2008*

## *Network inference: Protein-protein interactions (PPI), Enzyme-metabolite interactions, Target-ligand interactions, DNA binding site predictions*

- Protein-DNA: *Olman et al. J. Bioinform Comput Biol 2003*
- PPI: *Martin, Roe, Faulon, Bioinformatics 2005*
- Target-ligand interaction: *Oprea, Tropsha, Faulon, Nature Chemical Biology 2007*
- Enzyme-metabolite interactions, *Bioinformatics 2008*

# Predicting protein-ligand interactions

## Why:

Signaling network inference (protein-protein, protein-ligand interactions)

Drug discovery

Drug specificity, polypharmacology, promiscuous inhibitors

Metabolic network inference, genome annotation

Enzyme promiscuity, searching enzymes for novel reactions

## How:



Chemical informatics

Classical QSAR predicts compounds binding to a given target

Bioinformatics

Sequence homology predicts enzyme catalytic activity

Training sets are required for each target or each metabolic reaction



# ***Predicting protein-ligand interactions***

## **Why:**

**Signaling network inference (protein-protein, protein-ligand interactions)**

**Drug discovery**

**Drug specificity, polypharmacology, promiscuous inhibitors**

**Metabolic network inference, genome annotation**

**Enzyme promiscuity, searching enzymes for novel reactions**

## **How:**

**Chemical informatics**

**Classical QSAR predicts compounds binding to a given target**

**Bioinformatics**

**Sequence homology predicts enzyme catalytic activity**


**Training sets are required for each target or each metabolic reaction**

## **Our work:**

**A kernel method where learning is performed on the pair of interacting partners**

**Can use heterogeneous datasets found in Kegg, MetaCyc, BRENDA, MDDR, PubChem, DrugBank,..**

# Representing protein-ligand interaction: the tensor product



## DOPAMINE RECEPTOR DRD5

```
MLPPGSNGTAYPGQFALYQQLAQGNAVGGASAGAPPLGPSQVVTACLTLIIWTLGQVNL
VCAAIVRSRHLRANMTNVFIVSLAVSDFVALLVMPWKAVAQVAGYWPFGAFCDVWVAFD
IMCSTASILNLCVISVDRYWAISRPFYRKRKMTQRMALVMVGLAWTSLISIFVQLNW
HRDQAASWGGLDLPNNLANWTPWEEDFWEPDVNAENDSSLNRTYAISSSLISFYIPVAI
MIVTYTRIIYRIQVQIRRISSLERAAEAHQSCRSSAACAPDTSLRASIKKETKVLKTLV
IMGVFCWLPFFILNCMPFCSGHPEGPPAGFPCVSETTFDFVFWFGWANSSLNPIYA
FNADFQKVFAQLLGCSESRTPVETVNISELISYNQDIVFHKEIAAAYIHMMPNVATP
GNREVDNDEEEGPFDRMFQIYQTSPPDGPVAESVWELDCGEISLTKITPFTPNGFH
```

Protein: KRK,...,RKM,...,KMT

$p_1$        $p_2$        $p_3$

Protein x Ligand :

KRK C(=C C C),..., KRK N(C C H),...,KRK C(C C C H)  
RKM C(=C C C),..., RKM N(C C H),..., RKM C(C C C H)  
KMT C(=C C C),..., KMT N(C C H),..., KMT C(C C C H)

Ligand: C(=C C C),..., N(C C H),...,C(C C C H)

$c_1$        $c_2$        $c_3$

$$\sigma(P) = (p_1, p_2, \dots, p_n)$$

$$\sigma(C) = (c_1, c_2, \dots, c_n)$$


$$\sigma(P \otimes C) = (p_1 c_1, \dots, p_1 c_n, p_2 c_1, \dots, p_2 c_n, \dots, p_n c_1, \dots, p_n c_n)$$



# Finding new interactions?

KEGG database (Nov 2007) comprises 873 drug- target pairs between 121 human targets and 551 drugs. Tensor product gives accuracy > 90% with 5-fold cross validation

Independent test set composed of 298 interactions between FDA approved drugs and targets (extracted from DrugBank database). Only 32 interactions are in training set (KEGG)



**Accuracy = 67%**  
**Area Under the ROC Curve = 0.74**

class	Nbr such examples	Drug-target example
Target & drug not in training	94	Pinozide – Opioid receptor OPRD1
Target not in training	16	Fenoldopam – Dopamine receptor DRD5
Drug not in training	145	Perphenazine -Dopamine receptor DRD2

**These predictions cannot be made with classical QSAR or sequence homology**

# ***Predicting protein-ligand interactions***

## **Why:**

**Signaling network inference (protein-protein, protein-ligand interactions)**

**Drug discovery**

**Drug specificity, polypharmacology, promiscuous inhibitors**

**Metabolic network inference, genome annotation**

**Enzyme promiscuity, searching enzymes for novel reactions**

## **How:**

**Chemical informatics**

**Classical QSAR predicts compounds binding to a given target**

**Bioinformatics**

**Sequence homology predicts enzyme catalytic activity**

**Training sets are required for each target or each metabolic reaction**

**Virtual screening requires 3D structures**


## **Our work:**

**A a kernel method where learning is performed on the pair of interacting partners**

**Can use heterogeneous datasets found in Kegg, MDDR, PubChem, DrugBank,..**

# Representing enzyme-reaction interaction

Faulon JCICS 1994 :  $\sigma(\text{reaction}) = \sigma(\text{product}) - \sigma(\text{reactant})$



$$\sigma(3.1.1.1) = \sigma(\text{Alcohol}) + \sigma(\text{Carboxylate}) - \sigma(\text{Carboxylic ester}) - \sigma(\text{H}_2\text{O})$$

esterase YpfH (*E. coli* UTI89)

```


MKHDFHFVVQSPDKPAQQLLLL FHGVGDNPVAMG
EIGSWFAPLFPDALVVSVGGAEPGSGNP
AGRQWFSVQGITEDNRQARVNAIMPTFIETVRYW
QKQSGVGNATALIGFSQGAIMALES
IKAEPGLASRVIAFNTRYASLPETASTATTIHLI HGG
EDPVIDLAHAVAQAQALISAGGD
VTLDIVEDLGHAINRSMQLALDHLRYTIPKHYFD
EALSGGKPGDDDDVIEMM
    
```

0.0	[O=] ([C=])
1.0	[O-] ([C])
-1.0	[O] ([R] [C])
1.0	[O] ([R] [H])
-1.0	[O] ([H] [H])
1.0	[C] ([=O] [O-] [R])
-1.0	[C] ([=O] [O] [R])

1 MKH  
1 KHD  
1 HDF  
...

1.0	[O-] ([C])	MKH	1.0	[O-] ([C])	KHD	-1.0	[O-] ([C])	HDF	...
-1.0	[O] ([R] [C])	MKH	-1.0	[O] ([R] [C])	KHD	-1.0	[O] ([R] [C])	HDF	...
1.0	[O] ([R] [H])	MKH	1.0	[O] ([R] [H])	KHD	1.0	[O] ([R] [H])	HDF	...
-1.0	[O] ([H] [H])	MKH	-1.0	[O] ([H] [H])	KHD	-1.0	[O] ([H] [H])	HDF	...
1.0	[C] ([=O] [O-] [R])	MKH	1.0	[C] ([=O] [O-] [R])	KHD	1.0	[C] ([=O] [O-] [R])	HDF	...
-1.0	[C] ([=O] [O] [R])	MKH	-1.0	[C] ([=O] [O] [R])	KHD	-1.0	[C] ([=O] [O] [R])	HDF	...

# Probing enzyme promiscuity



- Cellulases from *T. fusca*, *S. degradans*, *X. campestris* found to catalyse xylans
- T. fusca* cellulases bind to Chitin (*Li, Wilson, Biotech. & Bioengineering, 2008*)

# Finding enzyme catalyzing novel reactions

Test set  
composed of  
enzymes and  
reactions  
accepted by  
NC-IUBMB  
in Sept. 2006  
(none were in  
training set)

Training set  
KEGG  
database

855,722 interactions  
3,905 reactions  
255,304 enzymes

EC class	# Positive Pairs	Acc.	Prec.	Sens.	Spec.
<a href="#">EC 1.1.1.290 4-phosphoerythronate dehydrogenase</a>	59	88.7	82.6	98.3	79.1
<a href="#">EC 1.13.11.52 indoleamine 2,3-dioxygenase</a>	13	76.9	76.9	76.9	76.9
<a href="#">EC 1.13.11.53 acireductone dioxygenase (Ni<sup>2+</sup>-requiring)</a>	11	86.4	83.3	90.9	81.8
<a href="#">EC 1.2.1.71 succinylglutamate-semialdehyde dehydrogenase</a>	55	87.5	82.3	95.5	79.5
<a href="#">EC 1.2.1.72 erythrose-4-phosphate dehydrogenase</a>	46	88.0	80.8	100.0	76.1
<a href="#">EC 1.8.4.11 peptide-methionine (S)-S-oxide reductase</a>	390	79.5	99.8	59.1	99.9
<a href="#">EC 2.6.1.81 succinylornithine transaminase</a>	21	81.0	72.7	100.0	61.9
<a href="#">EC 3.1.3.77 acireductone synthase</a>	160	89.4	82.5	100.0	78.8
<a href="#">EC 3.3.2.9 microsomal epoxide hydrolase</a>	17	84.3	82.3	88.2	80.4
<a href="#">EC 3.5.1.96 succinylglutamate desuccinylase</a>	49	88.6	81.6	100.0	77.1
<a href="#">EC 3.5.3.23 N-succinylarginine dihydrolase</a>	51	90.2	83.7	100.0	80.4
<a href="#">EC 4.2.1.109 methylthioribulose 1-phosphate dehydratase</a>	12	87.5	80.0	100.0	75.0
Average		85.7±4.3	82.4±6.3	92.4±12.6	78.9±8.4

# Sequence design

# ***Designing sequence using inverse QSAR (i-QSAR)***

## **QSAR:**

- activity =  $f$  (descriptors)

## **Inverse-QSAR:**

- descriptors =  $f^{-1}$ (activity)

- assemble sequences matching descriptors

# *i*-QSAR: Design ICAM-1 binding sequences (1)

## 1. QSAR/QSPR analysis

Peptides	IC <sub>50</sub>	Peptides	IC <sub>50</sub>
1. CLLRMRSAC	480	9. CLLRMRSVC	700
2. CILRMRSAC	190	10. CLLRMRSIC	580
3. CVLRMRSAC	>1000	11. CALRMRSIC	>1000
4. CLIRMRSAC	720	12. CLARMRSIC	>1000
5. CLVRMRSAC	>1000	13. CLLRARSIC	>1000
6. CLLKMRSAC	105	14. CLLRMASIC	>1000
7. CLLRMKSAC	90	15. CLLRMRAIC	710
8. CLLRMRLC	>1000	16. CILKMKSAC	40

### 47 descriptors in the training set


x1 C(CL) x6 L(LR) x11 R(MS) x16 S(AK) x21 I(LR)  
 x2 C(CV) x7 L(IR) x12 R(IM) x17 S(AR) x22 A(CS)  
 x3 C(CI) x8 L(CI) x13 M(RR) x18 S(RV) x23 K(MS)  
 x4 C(AC) x9 L(KL) x14 M(KR) x19 I(CS) x24 K(LM)  
 x5 L(CL) x10 R(LM) x15 S(IR) x20 I(CL) x25 V(CS)



MRL, SVR, PLS, ...

QSAR equation:

$$\begin{aligned}
 \text{Log}_{10}(\text{IC}_{50}) = & 2.81 - 0.739 x_2 - 0.574 x_8 \\
 & + 0.662 x_{13} + 0.728 x_{31} \\
 & + 0.727 x_{41} - 0.644 x_{37}
 \end{aligned}$$





# *i*-QSAR: Design ICAM-1 binding sequences (2)

1. QSAR/QSPR analysis

2. Integer equation builder

## Descriptors in the training set

x1 C(CL)	x6 L(LR)	x11 R(MS)	x16 S(AK)	x21 I(LR)
x2 C(CV)	x7 L(IR)	x12 R(IM)	x17 S(AR)	x22 A(CS)
x3 C(CI)	x8 L(CI)	x13 M(RR)	x18 S(RV)	x23 K(MS)
x4 C(AC)	x9 L(KL)	x14 M(KR)	x19 I(CS)	x24 K(LM)
x5 L(CL)	x10 R(LM)	x15 S(IR)	x20 I(CL)	x25 V(CS)

## Constraint Equations

$$2.81 - 0.739 x_2 - 0.574 x_8 + 0.662 x_{13} + 0.728 x_{31} + 0.727 x_{41} - 0.644 x_{37} - \text{target-IC}_{50} = 0$$

$$-x_{18} + x_{25} = 0$$

$$-x_2 + x_{25} = 0$$

$$-x_{11} + x_{15} + x_{17} + x_{18} = 0$$

$$x_{16} - x_{23} = 0$$

$$x_{15} - x_{19} = 0$$

$$x_{16} + x_{17} - x_{22} = 0$$

$$x_{10} + x_{11} + x_{12} - 2x_{13} - x_{14} = 0$$

$$-x_6 - x_7 + x_{10} = 0$$

$$x_{12} - x_{21} = 0$$

$$x_9 - x_{24} = 0$$

$$x_7 + x_8 - x_{20} - x_{21} = 0$$

$$-x_1 + x_5 + x_8 = 0$$

$$-x_3 + x_{19} + x_{20} = 0$$

$$(x_5 + x_6 + x_9) \% 2 = 0$$

$$x_4 - x_{22} = 0$$

$$(x_1 + x_2 + x_3 + x_4) \% 2 = 0$$

$$x_{14} - x_{23} - x_{24} = 0$$

$$\sum x_i = 9$$


# *i*-QSAR: Design ICAM-1 binding sequences (3)

1. QSAR/QSPR analysis


2. Integer equation builder

3. Integer (diophantine) equation solver

4. Structure generator (sequence assembly)



$$2 C(AC) + 2 A(CS) + S(AK) + K(MS) + M(KR) + R(MS) + S(AR) \rightarrow IC_{50} = 24.8$$



**CASKMRSAC**

Hamiltonian path in overlapping graph

Euler path in dual graph (Pevzner)

# *i*-QSAR: Design ICAM-1 binding sequences


## QSAR:

- activity =  $f$  (descriptors)

## Inverse-QSAR:

- descriptors =  $f^{-1}$ (activity)

- assemble sequences matching descriptors



$$2 C(AC) + 2 A(CS) + S(AK) + K(MS) + M(KR) + R(MS) + S(AR) = f^{-1}(<25)$$


CASKMRSAC

- Larson's lab (UNM) synthesized and tested in vitro (ELISA) and in vivo (cellular aggregation blocking assay)
  - CASKMRSAC ( $IC_{50} = 23$ , *i*-QSAR predicts 24.8)
  - CVSKMRSVC ( $IC_{50} = 28$ , *i*-QSAR predicts 37.3)
- Up to date most potent inhibitors known for ICAM-1 (JMGM 2004)

- Filed US Patent 2006

- Other *i*-QSAR examples : JMGM 2002, JCICS 2003, JCAMD 2005, Ind. Eng. Chem. Res 2005, JCIM 2006


# Designing proteins using QSAR and i-QSAR



Activity measured using DNS assay for 25 cellulase mutants (*CelA* from *Alicyclobacillus acidocaldarius* substrate carboxyl cellulose, pH 4.5)


Fox et al. Improving catalytic function by ProSAR-driven enzyme evolution, *Nature Biotech* **25**, 338 - 344 (2007)

Engineered halohydrin dehalogenase increases volumetric producing of Liptor 4,000 fold



# Network design


# Metabolic engineering: a Bio-retrosynthesis approach



# Metabolic engineering: Engineering *E. coli* to produce Taxol

Bio-retrosynthesis: Substrate and enzyme for Taxol?

*Taxus brevifolia*




Taxol



# Metabolic engineering: Engineering *E. coli* to produce Taxol

Bio-retrosynthesis: Substrate and enzyme for Taxol





# Metabolic engineering: Engineering *E. coli* to produce Taxol


Bio-retrosynthesis: Substrate and enzyme for 3'-N-Debenzoyltaxol?

- Code all known metabolic reactions  $R$  with neighborhood ( $\sigma(R)$ , method in Faulon, JCICS 1994)

- Search all metabolic substrates  $S$  such that  $R$  applied to  $S$  produces  $P$  = 3'-N-Debenzoyltaxol

(i.e,  $S \mid \sigma(S) = \sigma(P) - \sigma(R)$ , method in Faulon, JCICS 2001)

- For each solution  $S, R$ , search genomes for candidate enzymes using tensor product (Faulon et al. Bioinformatics 2008)



# Metabolic engineering: Engineering *E. coli* to produce Taxol

Bio-retrosynthesis: Substrate and enzyme for 3'-N-Debenzoyltaxol?


$\sigma$ ( BaccatinIII + (RS)- $\beta$ -phenylalanoyl-CoA )

=


$\sigma$ (Debenzoyltaxol + CoA)

-

$\sigma$ (propanoyl acyltransferase)




# Metabolic engineering: Engineering *E. coli* to produce Taxol



# Bio-retrosynthesis: which pathway to engineer?

Deoxyxylulose 5 phosphate pathway  
(Prokaryotes & Plants)




2x2 paths lead to squalene, do we need to engineer all? Which combination is best?

- Path enumeration

- Path ranking, a cost function, including

- Number of exogenous enzymes and organisms
- Number of predicted vs. documented enzymes is minimized.
- Metabolites inhibition
- Exogenous metabolites cytotoxicity
- Difficulties of inserting exogenous enzymes into plasmids or chromosomes
- Enzymes activity and pathway kinetics



# Drug candidates for bio-retrosynthesis

Among 916 FDA approved small drugs taken from DRUGBANK


Which ones are also metabolites of <i>E. coli</i> ?	- Metabolites searched in all <i>E coli</i> strains in KEGG	21
Which ones are also metabolites of <i>other organisms</i> ?	- Metabolites searched in all other organisms stored in KEGG	42
Which ones are similar to some metabolites of <i>E. coli</i> ?	- Similarity search using chemical fingerprints	36
Which ones are similar to some metabolites of <i>other organisms</i> ?	- Similarity search using chemical fingerprints	32

# Examples for bio-retrosynthesis

Which ones are also metabolites of *other organism*?

Taxol (diterpenoids biosynthesis)



Which ones are similar to some metabolites of *E. coli*?



Ganciclovir

Tanimoto= 0.69


Guanosine  
Purine  
metabolism




Cytarabine

Tanimoto= 0.80

Deoxycytidine  
Pyrimidine  
metabolism




Which ones are similar to some metabolites of *other organism*?



Hydromorphone








Tanimoto= 0.82

Morphinone  
Alkaloid biosynthesis I  
(*Streptococcus sanguinis*)



# Funding sources

- Genopole/ATIGE  
Bioretrosynthesis
- CNRS/Interface Physique Chimie Biologie  
Toxicity prediction

Source		Title
DOE/Bioenergy Research Centers (www.jbei.org)	2007-08	Joint Bioenergy Institute  
DOE/Sandia LDRD program	2005-08	Shotgun protein sequencing 
DOE/Grand Challenge program	2005-08	Signaling networks Modeling immune system 
DOE/Sandia LDRD program	2005-08	Molecular design 
NIH/PubChem	2004-07	Molecular libraries screening centers 
DOE/Sandia LDRD program	2002-05	Reverse engineering transcriptional regulatory networks
DOE/Genome to Life Program	2002-05	Protein network inference 

# ***Acknowledgements***

**M. Misra, Sandia**

**Don Visco, R. Pophale, A. Kotu, D. Weiss, TTU**

**M. Brown, Sandia**

**C. Churchwell, Sandia**

**(QSAR)**

**(QSAR & iQSAR)**

**(QSAR & iQSAR)**

**(sequence design)**

**D. Roe, S. Martin, R. Carr, Sandia**

**K. Sale, Sandia**

**R. Sapra and B. Simmons, JBEI**

**(SVMs and network inference)**

**(training sets & QSAR)**

**(enzyme assays)**

**T. Oprea, UNM**

**R. Larson's lab, UNM**

**(systems chemical biology)**

**(inhibitor assay)**